Candel reports CAN-2409 phase 2 interim data: 71.4% survival at 36 months vs 16.7% in borderline PDAC

Candel Therapeutics, Inc.

Estimated overall survival rate 71.4% at 24 & 36 months for CAN-2409 arm vs 16.7% control in borderline resectable PDAC.
Median overall survival not yet reached in CAN-2409 arm; control arm median OS was 12.5 months.
Robust immune activation: dense aggregates of CD8+ granzyme B+ T cells, dendritic cells, and B cells in tumor.
No dose-limiting toxicities or pancreatitis reported; multiple injections generally well tolerated.
5 of 7 CAN-2409 patients alive at data cutoff; two survived >45 months. Control: 1 of 6 alive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.